GSDMD and Parkinson disease: The NLRP3 inhibitor ACT001 was evaluated for therapeutic potential.<h4>Results</h4>PD patients and MPTP-treated mice showed increased peripheral G-MDSCs with reduced NLRP3/GSDMD activation.